Merck’s WINREVAIR Meets Primary Endpoint in Phase 2 Pulmonary Hypertension Study
Reuters
Nov 18
Merck's WINREVAIR Meets Primary Endpoint in Phase 2 Pulmonary Hypertension Study
Merck & Co. Inc. announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ (sotatercept-csrk) in adults with combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in pulmonary vascular resistance (PVR) at 24 weeks compared to placebo. The safety profile observed was generally consistent with the known safety profile for WINREVAIR. Merck plans to present the results at a future scientific congress and intends to proceed with Phase 3 development in this patient population. WINREVAIR is currently approved in over 50 countries for the treatment of adults with pulmonary arterial hypertension (PAH).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251118918484) on November 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.